Charles Schwab Investment Management Inc. lifted its stake in Biohaven Ltd. (NYSE:BHVN - Free Report) by 10.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 701,314 shares of the company's stock after purchasing an additional 68,624 shares during the period. Charles Schwab Investment Management Inc. owned 0.69% of Biohaven worth $26,194,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently bought and sold shares of BHVN. Spire Wealth Management bought a new position in shares of Biohaven in the fourth quarter worth about $56,000. KBC Group NV increased its holdings in Biohaven by 24.5% in the 3rd quarter. KBC Group NV now owns 2,250 shares of the company's stock worth $112,000 after acquiring an additional 443 shares in the last quarter. Amalgamated Bank raised its stake in Biohaven by 21.9% during the 4th quarter. Amalgamated Bank now owns 2,929 shares of the company's stock worth $109,000 after acquiring an additional 527 shares during the period. US Bancorp DE lifted its holdings in Biohaven by 36.7% during the fourth quarter. US Bancorp DE now owns 2,971 shares of the company's stock valued at $111,000 after purchasing an additional 798 shares in the last quarter. Finally, Capstone Investment Advisors LLC purchased a new stake in shares of Biohaven in the third quarter worth $250,000. 88.78% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several brokerages recently weighed in on BHVN. Deutsche Bank Aktiengesellschaft began coverage on shares of Biohaven in a report on Tuesday, February 11th. They issued a "buy" rating and a $65.00 target price for the company. Morgan Stanley dropped their price objective on Biohaven from $69.00 to $63.00 and set an "overweight" rating for the company in a research note on Friday, March 7th. JPMorgan Chase & Co. decreased their target price on Biohaven from $72.00 to $68.00 and set an "overweight" rating on the stock in a research note on Wednesday, March 5th. Royal Bank of Canada restated an "outperform" rating and issued a $61.00 price target on shares of Biohaven in a research note on Tuesday, March 4th. Finally, HC Wainwright reiterated a "buy" rating and set a $54.00 price objective on shares of Biohaven in a research report on Tuesday, March 4th. Fourteen research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Biohaven has a consensus rating of "Buy" and an average price target of $63.15.
Get Our Latest Report on Biohaven
Biohaven Stock Up 1.5 %
NYSE BHVN traded up $0.43 during trading hours on Friday, hitting $28.61. 632,211 shares of the company were exchanged, compared to its average volume of 1,058,766. Biohaven Ltd. has a 52 week low of $26.80 and a 52 week high of $60.46. The stock has a 50-day moving average price of $36.06 and a 200 day moving average price of $41.68. The stock has a market cap of $2.92 billion, a PE ratio of -3.06 and a beta of 1.27.
Biohaven (NYSE:BHVN - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($1.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.56) by ($0.29). As a group, sell-side analysts anticipate that Biohaven Ltd. will post -8.9 earnings per share for the current year.
Insiders Place Their Bets
In related news, Director John W. Childs purchased 32,700 shares of the business's stock in a transaction dated Tuesday, March 4th. The shares were purchased at an average cost of $30.47 per share, for a total transaction of $996,369.00. Following the completion of the acquisition, the director now owns 2,320,571 shares in the company, valued at approximately $70,707,798.37. This trade represents a 1.43 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 16.00% of the company's stock.
About Biohaven
(
Free Report)
Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.
Further Reading
Before you consider Biohaven, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biohaven wasn't on the list.
While Biohaven currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
